Kymera Therapeutics (KYMR) reported a Q4 net loss Thursday of $0.88 per diluted share, wider than the loss of $0.25 a year earlier.
Analysts polled by FactSet expected a loss of $0.86.
Collaboration revenue for the quarter ended Dec. 31 was $7.4 million, down from $47.9 million a year earlier.
Analysts surveyed by FactSet expected $14.4 million.
Kymera said that as of Dec. 31, it had about $851 million in cash, cash equivalents, and investments, which it expects to provide a cash runway into mid-2027.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。